Repurposing the phenylthiazole scaffold with 1,3,4-oxadiazole for selective, potent and well-tolerated antifungal

Mohamed Hagras1, Hany G Ezzat1, Abdelrahman A Abuelkhir1

  • 1Department of Pharmaceutical Organic Chemistry, College of Pharmacy, Al-Azhar University Cairo 11884 Egypt m.hagrs@azhar.edu.eg.

RSC Advances
|March 28, 2025
PubMed

Insights

Novel phenylthiazole-based oxadiazole derivatives show potent antifungal activity against resistant strains like Candida auris. Compound 35 is a promising lead candidate with a favorable safety profile, addressing the urgent need for new antifungal therapies.

Area of Science:

  • Medicinal Chemistry
  • Mycology
  • Infectious Diseases

Background:

  • Invasive fungal infections (IFIs) pose a significant threat, especially to immunocompromised patients, with high mortality rates.
  • Increasing antifungal resistance necessitates the development of novel therapeutic agents.
  • Existing treatments face challenges due to resistance and toxicity.

Purpose of the Study:

  • To rationally design and synthesize novel phenylthiazole-based oxadiazole derivatives.
  • To evaluate the antifungal activity and selectivity of these derivatives against resistant fungal strains.
  • To identify a lead compound with enhanced potency and an improved safety profile.

Main Methods:

  • Rational drug design and synthesis of phenylthiazole-based oxadiazole derivatives.
  • Antifungal susceptibility testing using Minimum Inhibitory Concentration (MIC) assays.
  • Cytotoxicity and hemolytic activity assays to assess safety profile.

Main Results:

  • Compound 35 demonstrated potent activity against *Candida albicans*, *Candida glabrata*, and multidrug-resistant *Candida auris*.
  • MIC values for compound 35 ranged from 0.5-4 μg mL⁻¹, outperforming fluconazole.
  • Compound 35 exhibited minimal cytotoxicity and negligible hemolytic activity, suggesting a favorable safety profile.

Conclusions:

  • Phenylthiazole-based oxadiazole derivatives represent a promising class of novel antifungal agents.
  • Compound 35 is a potential lead candidate for developing new treatments against invasive fungal infections, including those caused by resistant strains.
  • The favorable safety profile of compound 35 warrants further investigation for clinical development.

Related Concept Videos

Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview01:07

Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview

In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
Aryldiazonium Salts to Azo Dyes: Diazo Coupling01:11

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the para position.
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...